Molecular diagnostics has emerged dramatically over the last two decades, as advanced technologies have driven this industry towards the next level of significance. Companies which already have adopted molecular diagnostic methods are now benefitted by increased accuracy and improved sensitivities in their tests compared to others. These new methods have greatly enhanced the discovery of many microbial infections, as well as genetic illnesses. Those who were hesitating due to the challenges and expense of opening a molecular lab now run the risk of being at a competitive disadvantage.
Molecular Diagnostics Industry
Molecular diagnostics has paved way for collaboration among many companies to add up their strengths. Through the collaboration, they intend to strengthen their hold in the molecular diagnostic market and develop an integrated clinical workflow solution and provide mass access to molecular diagnostics. Tie-ups with companies from other domains are mainly aimed at marketing of diagnostic tests. Only a handful of companies controlled more than two-thirds or more of the market for molecular tests. Companies like Roche will continue to lead the product portfolio includes molecular diagnostic tests for oncology, virology, microbiology, and blood screening. Multiple insurance providers are associated with them as payers of high-end medical tests.
Emerging Market Led by DNA Testing
The global molecular diagnostics market has reached beyond six billion USD in recent times according to some business reports. New technologies, innovations in medical science and expanded applications for tests have been fueling steady growth in the field. The business scope for it has its spectrum is not limited to one field of study. Molecular techniques are utilized in diverse fields like biochemistry, cellular sciences, genetics, infectious disease, oncology, hematology, and pharmacology.
Majority of the market for testing is derived from blood screening and tests related to infectious diseases. Personalized medicine is the new trend emerging with technologies that depend on DNA sequencing and molecular diagnostics. DNA sequencing is becoming a primary reason for the growth of molecular diagnostics. Personalization is the best when the approach to patients care is preventive care, which relies on proper diagnostic care or therapeutic remedies.
Clinical Testing Goes Molecular
Opening a molecular lab is a complex project demanding high-end instruments and expert to operate them. Setting up a sophisticated molecular lab is easier today because of the developments in the technology. Complex tests and bulky equipment are becoming more digital and user-friendly, gradually loaded with automated functioning. It also offers monitoring and control systems to ensure quality results.
It’s been more challenging to demonstrate the clinical utility of tests for broad patient populations. Targeted tests will continue to be the first choice for the majority of the patients. It will be more imperative than ever for clinical labs to have moldable solutions, with both targeted tests available.
A major challenge in the form of Antibiotic resistance is bound to have a long-term impact on the molecular diagnostics space. There are three elements – an integrated approach of rapid testing, antimicrobial stewardship programs, and clear actions based on results, which are required to address such a public health crisis.
Molecular diagnostics is advancing to provide most laboratory tests in infections and genetics. Genome sequence databases within and between species provide the information necessary to develop sensitive and specific diagnostic assays. In fact, microorganisms are nowadays classified on the basis of sequence rather than phenotype.
No comments:
Post a Comment